iSpecimen Expands Provider Network to Enhance Support for Women’s Health Research
13 September 2023 - 9:30PM
iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”),
an online global marketplace that connects scientists requiring
biospecimens for medical research with a network of healthcare
specimen providers, announced today that the Company has recently
expanded its global provider network to help advance women’s health
research. These strategic collaborations significantly expand the
availability of high-quality tissue and biofluid specimens for
studies on cervical, uterine and breast cancers; reproductive
health; cardiovascular disease; autoimmune disorders and STIs.
Among the new providers, one partner spans five
sites in Ohio, Texas and Mississippi, which will help to unlock
access to specimens from approximately 640,000 patients. These
specimens encompass a comprehensive range of samples, including
tumor tissues, adjacent normal tissues, plasma, whole blood, bone
marrow, urine, stool, peripheral blood mononuclear cells (PBMCs),
hematopoietic stem cells, immune cells, buffy coat and serum.
iSpecimen’s expanded provider network also lends crucial support
for reproductive research, with a significant pool of pregnancy
donors under age 35, including those in their third trimester,
along with urine samples from Cepheid GeneXpert CT/NG PCR
tests.
"Our ability to equip researchers with unmatched
access to the vital specimens they require includes doing so for a
number of important women's health conditions, an area of research
that continues to demand the industry’s attention and dedication,”
said Tracy Curley, iSpecimen’s CEO. "Adding these biospecimen
providers demonstrates our commitment to advancing scientific
discovery in women's health and ensuring biospecimen availability
for this potentially lifesaving research.”
The iSpecimen Marketplace platform offers
precise customization, allowing researchers to specify patient age,
gender, race, condition, severity, blood type, treatment status,
test results, outcomes, smoking status, family history and more.
Comprised of over 230 providers, iSpecimen's global biospecimen
provider network offers researchers access to clinically collected
samples, banked tissues, biofluids and prospective collections from
diverse female populations.
About iSpecimeniSpecimen
(Nasdaq: ISPC) offers an online marketplace for human biospecimens,
connecting scientists in commercial and non-profit organizations
with healthcare providers that have access to patients and
specimens needed for medical discovery. Proprietary, cloud-based
technology enables scientists to intuitively search for specimens
and patients across a federated partner network of hospitals, labs,
biobanks, blood centers and other healthcare organizations. For
more information, please visit www.ispecimen.com.
Forward Looking StatementsThis press release
may contain forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended. Such
forward-looking statements are characterized by future or
conditional verbs such as "may," "will," "expect," "intend,"
"anticipate," “believe," "estimate" and "continue" or similar
words. You should read statements that contain these words
carefully because they discuss future expectations and plans, which
contain projections of future results of operations or financial
condition or state other forward-looking information.
Forward-looking statements are predictions,
projections and other statements about future events that are based
on current expectations and assumptions and, as a result, are
subject to risks and uncertainties. Many factors could cause actual
future events to differ materially from the forward-looking
statements in this press release, including but not limited to the
risk factors contained in the Company's filings with the Securities
and Exchange Commission, which are available for review at
www.sec.gov. Forward-looking statements speak only as of the date
they are made. New risks and uncertainties arise over time, and it
is not possible for the Company to predict those events or how they
may affect the Company. If a change to the events and circumstances
reflected in the Company's forward-looking statements occurs, the
Company's business, financial condition and operating results may
vary materially from those expressed in the Company's
forward-looking statements.
Readers are cautioned not to put undue reliance
on forward-looking statements, and the Company assumes no
obligation and does not intend to update or revise these
forward-looking statements, whether as a result of new information,
future events or otherwise.
For further information, please contact:
Investor ContactsKCSA Strategic
CommunicationsPhil Carlson / Erika Kay iSpecimen@kcsa.com
Media ContactsKCSA Strategic
CommunicationsRaquel Cona / Shana Marino iSpecimen@kcsa.com
iSpecimen (NASDAQ:ISPC)
Historical Stock Chart
From Apr 2024 to May 2024
iSpecimen (NASDAQ:ISPC)
Historical Stock Chart
From May 2023 to May 2024